Navigation Links
Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
Date:10/23/2008

-Sapirstein to Present Company Overview-

PRINCETON, N.J. and SAN DIEGO, Oct. 23 /PRNewswire/ -- Tobira Therapeutics, Inc., a company focused on the development of medicines with novel mechanisms of actions for infectious diseases, today announced it will present a corporate overview at the 2008 BIO Investor Forum. James Sapirstein, Chief Executive Officer and President will summarize the current status of the company including the status of TBR-652, a CCR5 antagonist in development for HIV-1 infection in adults. The presentation is scheduled for October 30, 2008 at 9:00 AM PST at The Palace Hotel, Two New Montgomery Street, San Francisco, Calif.

"We are delighted to share the growth Tobira Therapeutics, Inc. has experienced in the last 18 months at the BIO Investor Forum," said James Sapirstein. "This is a unique opportunity to review the great potential that we have to offer." Tobira Therapeutics is a clinical stage company and is not developing new technologies. The company is expanding its pipeline by being the partner of choice for suppliers, researchers, and alliance partners. A key component of Tobira's strategy is to acquire global rights to additional product candidates in infectious diseases, while continuing to develop and commercialize new products and line extensions.

The BIO Investor Forum will feature more than 190 public and venture-stage company presentations, in addition to drug and technology therapeutic workshops, breakout sessions, one-on-one investor meetings, and networking with industry executives and investors.

About Tobira Therapeutics, Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

Contact:

Tobira Therapeutics Inc.

Antoinette Bobbitt, Senior Director, Corporate and Business Development

abobbitt@tobiratherapeutics.com Tel: +1 609-897-1102

http://www.tobiratherapeutics.com


'/>"/>
SOURCE Tobira Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tobira Therapeutics Inc. Announces Senior Management Team
2. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
3. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
4. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
5. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
6. Cell Therapeutics, Inc. Announces Reverse Stock Split
7. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
10. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
11. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):